Moreover, AdC7-SP/E1A-ΔE3 could efficaciously kill NCI-H508 and Huh7 in vitro and in vivo, indicating that AdC7-SP/E1A-ΔE3 has the potential to treat such cancers. This evidence concerns the gene TFF2 and cancer.